Cancer Genetics to Report Fourth Quarter & Fiscal 2015 Financial Results on Thursday, March 10

RUTHERFORD, N.J., March 03, 2016 -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will report financial results for the fourth quarter and fiscal year ended December 31, 2015 after the market close on Thursday, March 10, 2016.  The company will also hold a live investor conference call and webcast at 5:00 pm Eastern.

Conference Call & Webcast
Thursday, March 10th @ 5:00pm Eastern Time
Domestic:                                888-438-5525
International:                           888-438-5525
Conference ID:                        9859224
Webcast:                                 http://public.viavid.com/index.php?id=118421

Replays – Available through March 24, 2016
Domestic:                                877-870-5176
International:                           858-384-5517
Conference ID:                        9859224

About Cancer Genetics
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow us:

     Internet: http://www.cancergenetics.com

     Twitter: @Cancer_Genetics

     Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended September 30, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Contact:
Investor Relations
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568

Media Relations
Marie-Agnes Patrone-Michellod, PhD.
Cancer Genetics, Inc.
201-528-9200
[email protected]